127999-16-0

Basic information

• Product Name: Tr-PEG7-alcohol
• Synonyms: Tr-PEG7-alcohol;Tr-PEG7
• CAS NO: 127999-16-0
• Molecular Formula: C₃₁H₄₀O₇
• Molecular Weight: 524.6451
• Mol File: 127999-16-0.mol

Chemical Properties

• Appearance: /
• Solubility: Soluble in DMSO, DCM, DMF
• CAS DataBase Reference: Tr-PEG7-alcohol(CAS DataBase Reference)
• NIST Chemistry Reference: Tr-PEG7-alcohol(127999-16-0)
• EPA Substance Registry System: Tr-PEG7-alcohol(127999-16-0)

Safety Data

• Hazardous Substances Data: 127999-16-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Tr-PEG7-alcohol is used as a solubility enhancer for improving the water solubility of hydrophobic drugs, facilitating their delivery and absorption in the body. The trityl group can be strategically removed under specific conditions, allowing for controlled release or activation of the drug.
Used in Drug Delivery Systems:
Tr-PEG7-alcohol is used as a component in the design of drug delivery systems, particularly for targeted and controlled drug release. The PEG linker provides stability and solubility, while the trityl group can be removed under specific conditions to release the active drug.
Used in Bioconjugation and Labeling:
Tr-PEG7-alcohol is used as a versatile building block in the synthesis of bioconjugates and for labeling biomolecules. The trityl group can be used to protect functional groups during synthesis, while the PEG linker can improve the solubility and stability of the final product.
Used in Cosmetics and Personal Care Industry:
Tr-PEG7-alcohol is used as an ingredient in cosmetics and personal care products to enhance the solubility and stability of active ingredients, as well as to improve the texture and feel of the formulations.
Used in Material Science:
Tr-PEG7-alcohol can be utilized in the development of hydrogels and other biomaterials, where the PEG linker provides enhanced water solubility and the trityl group can be removed to control the material's properties or to release encapsulated substances.

Upstream product

• 2615-15-8 pentaethylene glycol 
• 76-83-5 trityl chloride 
• 146462-59-1 1-(methylsulfonyl)-10-(triphenylcarbinyl)-1,4,7,10-tetraoxadecane 
• 112-27-6 2,2'-[1,2-ethanediylbis(oxy)]bisethanol 
• 112-60-7 Tetraethylene glycol 
• 146462-58-0 2-<2-(triphenylmethoxy)ethoxy>ethyl methanesulfonate 
• 105589-77-3 2-(2-trityloxyethoxy)ethanol 
• 133699-09-9 10,10,10-triphenyl-3,6,9-trioxadecan-1-ol 
• 76-84-6 triphenylmethyl alcohol 

Downstream Products

• 1274892-60-2 2-{2-[2-(2-{2-[2-(2-azido-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethanol 
• 745048-17-3 1,1,1-triphenyl-2,5,8,11,14,17,20-heptaoxadocosan-22-ol 
• 745048-18-4 22-azido-1,1,1-triphenyl-2,5,8,11,14,17,20-heptaoxadocosane 
• 850723-16-9 methanesulfonic acid 2-{2-[2-(2-{2-[2-(2-trityloxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethyl ester 
• 778596-26-2 tert-butyl 1-hydroxy-3,6,9,12,15,18,21,24,27,30-decaoxatritriacontan-33-oate 
• 778596-28-4 3-(2-{2-[2-(2-{2-[2-(2-{2-[2-(2-mercapto-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-propionic acid tert-butyl ester 
• 778596-20-6 34-(p-toluenesulfonyl)-4,7,10,13,16,19,22,25,28,31,34-undecaoxatetracontanoic acid tert-butyl ester 
• 877239-08-2 1-azide-31,31,31-triphenyl-3,6,9,12,15,18,21,24,27,30-decaoxahentriacontanol 
• 2615-15-8 pentaethylene glycol 
• 39160-70-8 3,6,9,12,15,18-hexaoxa-1-octadecyl amine 
• 125274-14-8 2-{2-[2-(2-{2-[2-(2-{2-[2-(2-trityloxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethanol 
• 129449-09-8 29-amino-3,6,9,12,15,18,21,24,27-nonaoxanonacosan-1-ol 

Relevant articles and documents

A-B-A-B-A block amphiphiles. Balance between hydrophilic and hydrophobic segmentation

Six penta-block amphiphiles of the general structure A-B-A-B-A or B-A-B-A-B (where A = a hydrophilic ether and B = a hydrophobic carbon chain) were synthesized and examined via water solubilities, surface activities, cloud points, and self-diffusion coeff

Ligand-Phospholipid Conjugation: A Versatile Strategy for Developing Long-Acting Ligands That Bind to Membrane Proteins by Restricting the Subcellular Localization of the Ligand

We hypothesized that if drug localization can be restricted to a particular subcellular domain where their target proteins reside, the drugs could bind to their target proteins without being metabolized and/or excreted, which would significantly extend the half-life of the corresponding drug-target complex. Thus, we designed ligand-phospholipid conjugates in which the ligand is conjugated with a phospholipid through a polyethylene glycol linker to restrict the subcellular localization of the ligand in the vicinity of the lipid bilayer. Here, we present the design, synthesis, pharmacological activity, and binding mode analysis of ligand-phospholipid conjugates with muscarinic acetylcholine receptors as the target proteins. These results demonstrate that ligand-phospholipid conjugation can be a versatile strategy for developing long-acting ligands that bind to membrane proteins in drug discovery.

Highly efficient synthesis of monodisperse poly(ethylene glycols) and derivatives through macrocyclization of oligo(ethylene glycols)

A macrocyclic sulfate (MCS)-based approach to monodisperse poly(ethylene glycols) (M-PEGs) and their monofunctionalized derivatives has been developed. Macrocyclization of oligo(ethylene glycols) (OEGs) provides MCS (up to a 62-membered macrocycle) as versatile precursors for a range of monofunctionalized M-PEGs. Through iterative nucleophilic ring-opening reactions of MCS without performing group protection and activation, a series of M-PEGs, including the unprecedented 64-mer (2850Da), can be readily prepared. Synthetic simplicity coupled with versatility of this new strategy may pave the way for broader applications of M-PEGs. Macrocycles make synthesis easier: Convenient macrocyclization of the OEGs provides versatile macrocyclic sulfates. These compounds are cornerstones for both monofunctionalization of OEGs and highly efficient synthesis of monodisperse PEGs and derivatives, including an unprecedented 64-mer.

Synthesis and the structure to property relationship of monoperfluoroalkyl polyethylene glycol

Monoprotected polyethylene glycols (PEG) react with epichlorohydrin to furnish PEGylated epoxides. The latter were converted into the corresponding α-(2-F-alkylethyl)thiomethyl polyethylene glycols by treatment with 2-F-alkylethanethiol. Surface activity

HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF

The present invention relates to compounds of general formula (I) and the tautomers and the salts thereof, particularly the pharmaceutically acceptable salts thereof with inorganic or organic acids and bases, which have valuable pharmacological properties, particularly an inhibitory effect on epithelial sodium channels, the use thereof for the treatment of diseases, particularly diseases of the lungs and airways.

OLIGOMER CONJUGATES OF LIDOCAINE AND ITS DERIVATIVES

The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer.

GALACTOSE DERIVATIVE, DRUG CARRIER AND MEDICINAL COMPOSITION

The object of the invention is to provide a novel and useful galactose derivative constituting a drug carrier by which a medicine can be efficiently transferred into the liver, a drug carrier comprising the derivative, and a pharmaceutical composition comprising the carrier and a medicine. The present invention relates to a galactose derivative made up of galactose, a suitable spacer and a certain lipid, a drug carrier comprising the derivative and a cationic lipid, and a pharmaceutical composition comprising the carrier and a medicine (preferably a double strand RNA, a double strand DNA, an oligo nucleic acid) .

Fluorescent pirenzepine derivatives as potential bitopic ligands of the human M1 muscarinic receptor

Following a recent description of fluorescence resonance energy transfer between enhanced green fluorescent protein (EGFP)-fused human muscarinic M1 receptors and Bodipy-labeled pirenzepine, we synthesized seven fluorescent derivatives of this antagonist in order to further characterize ligand-receptor interactions. These compounds carry Bodipy [558/568], Rhodamine Red-X [560/580], or Fluorolink Cy3 [550/570] fluorophores connected to pirenzepine through various linkers. All molecules reversibly bind with high affinity to M1 receptors (radioligand and energy transfer binding experiments) provided that the linker contains more than six atoms. The energy transfer efficiency exhibits modest variations among ligands, indicating that the distance separating EGFP from the fluorophores remains almost constant. This also supports the notion that the fluorophores may bind to the receptor protein. Kinetic analyses reveal that the dissociation of two Bodipy derivatives (10 or 12 atom long linkers) is sensitive to the presence of the allosteric modulator brucine, while that of all other molecules (15-24 atom long linkers) is not. The data favor the idea that these analogues might interact with both the acetylcholine and the brucine binding domains.

Synthesis of taxoids with improved cytotoxicity and solubility for use in tumor-specific delivery

To develop effective taxane-antibody immunoconjugates, we have prepared a series of modified taxanes that have both improved toxicity and solubility in aqueous systems as compared to paclitaxel (1a). These taxanes have been modified at either the C-10 or

Multigram Synthesis of Well-Defined Extended Bifunctional Polyethylene Glycol (PEG) Chains

A series of novel, well-defined, unsymmetrical poly(ethylene glycol) chains of the type X(OCH2-CH2)nY (where X = protecting group; Y = nucleofuge or a different protecting group; n = 3, 6, 9, 12, 15, 18, and 24) were prepared in high yields by applying orthogonal protecting groups. The purity of the compounds was fully verified by elemental and high-resolution mass spectrometry analyses.